# V1 Empirics Check — openai/gpt-5.1-codex-mini (Variant A)

**Model:** openai/gpt-5.1-codex-mini
**Variant:** A
**Date:** 2026-03-30T11:09:28.872935

---

**Idea Fidelity**

The paper faithfully pursues the manifest’s core idea: using ARCOS data to construct county-level distributor HHIs and exploiting national merger waves as a shift-share instrument for concentration. The key elements from the manifest—178 million ARCOS transactions, county-level HHI, merger-driven variation, and the regulatory/policy motivation regarding distributor market power—are all addressed. One minor omission is a deeper discussion of the three specific mergers’ timelines and geographic scopes beyond the high-level summary; fleshing this out would strengthen the linkage to the instrument construction described in the manifest.

**Summary**

This paper opens the pharmaceutical supply chain by constructing county-year distributor concentration measures from ARCOS and uses a shift-share IV based on national distributor mergers to estimate the causal effect of local distributor concentration on opioid pill supply (2006–2012). The striking empirical finding is that increased concentration reduces per capita opioid shipments and—suggestively—overdose mortality, contrary to the narrative that concentrated middlemen fueled the epidemic. The paper argues that competitive pressures incentivized distributors to flood markets with pills while concentrated distributors faced more scrutiny and restrained volumes.

**Essential Points**

1. **Exclusion Restriction Needs Stronger Support.** The narrative that mergers were exogenous to county-level demand is plausible, but the instrument might still capture other channels, such as merger-induced compliance changes, supply disruptions, or redistribution of shipments across counties. Provide direct evidence (e.g., event-study patterns around merger dates, placebo counties unaffected by the merger geography, or falsification using non-opioid shipments) to bolster the assumption that merger-driven shifts only operate through concentration rather than through general shocks to distribution capacity or compliance behavior.

2. **First-Stage Variation and Monotonicity.** The first-stage R² (≈6%) and the claim that “predicted concentration weakly pushes actual concentration” would be more convincing if the paper documented how the instrument moved real shares in aggregate and across counties. Can the authors show, for example, that merger-affected counties actually saw the predicted increase/decrease in specific distributors’ shares over time? Without this, the IV may suffer from weak or heterogeneous compliance, and the LATE interpretation remains opaque.

3. **Interpretation in Levels vs. Log Outcome.** The main effect is reported in levels (pills per capita), but the robustness checks show the log specification flips sign and becomes imprecise. This inconsistency raises questions about the practical magnitude and policy relevance of the result. Clarify why the level effect is preferred, and investigate whether differential skewness or outlier counties drive the result. If the level effect is concentrated in small counties (as suggested by population-weighted attenuation), this needs to be highlighted in the interpretation.

**Suggestions**

- **Strengthen Description of Merger “Shifts.”** Expand the institutional narrative around each merger—including timing, geographic footprint, and pre-merger county footprints—so readers can assess how national share changes translate into local predicted HHIs. Presenting a table that links each merger to changes in the national share ratios (the “shifts” in the Bartik design) and showing how these shifts vary over time would demystify the instrument.

- **Provide Event-Time Graphs.** Plot average importer-level HHI and line up the timing of mergers to visualize whether concentration jumps coincide with merger dates. An event-study-style figure (even aggregated) would help readers assess dynamic effects and pre-trends, supporting the exclusion restriction.

- **Examine Alternative Outcomes and Placebos.** Incorporate placebo outcomes unlikely to be affected by opioid distribution (e.g., shipments of non-opioid drugs or employment in unrelated sectors) to show that the instrument is not capturing spurious national shocks. Similarly, testing the instrument’s effect on hydrocodone or oxycodone subcomponents before the relevant merger can provide further reassurance that the effect is specific to opioid supply.

- **Detail the Population Effect.** The significant negative coefficient on population in the balance test suggests differential exposure. Explore heterogeneous effects by county size or urban/rural status to see whether the competitive flood mechanism operates differently across contexts. This can both explain why the population-weighted coefficient shrinks and reveal where policy interventions would be most effective.

- **Clarify the Mechanism Linking Competition to Oversupply.** The paper argues that competition fast-tracks volume and evades scrutiny, but it would benefit from additional empirical or theoretical support. For example, demonstrate whether counties with more distributors indeed experienced faster shipment growth pre-merger, or cite/R, present evidence about DEA scrutiny intensity per distributor size. If possible, show that counties that became more concentrated post-merger saw slower growth in shipments per distributor or fewer flagged suspicious orders.

- **Address the Log Specification Carefully.** If log pills per capita is unreliable due to zero inflation or extreme skew (common in ARCOS), explain this in the text and consider alternative transformations (e.g., inverse hyperbolic sine). Provide a robustness table with trimmed samples or winsorized outcomes if outliers drive the discrepancy between levels and logs.

- **Discuss Reduction in Overdose Deaths More Conservatively.** The mortality result is suggestive but modest. Clarify the potential lags between shipments and deaths, and consider alternative timing assumptions (e.g., using lagged instrumented HHI) to ensure the reduced-form effect isn’t driven by simultaneous shocks to reporting or mortality reporting quality.

- **Clarify SDE Interpretation.** In Appendix B, the standardized effect sizes are labeled “Moderate negative,” but the main text describes a 4.2% reduction. Reconcile these interpretations explicitly so the reader understands how economically meaningful the effect is and how it compares to other drivers of pill supply.

- **Detail the Data Processing More Quantitatively.** The data appendix mentions matching issues (94.6% match rate). Summarize any potential biases introduced by dropping unmatched counties, and confirm that results are not sensitive to their exclusion. If there are concerns about data quality in certain states (e.g., due to reporting lags), mention whether robustness checks were run without those states.

- **Anticipate Counterarguments from Litigation.** Since the policy takeaway directly challenges the assumption behind major lawsuits, it would be helpful to reconcile the findings with the documented compliance failures of the Big Three. Could the same firms be both highly compliant when concentrated and aggressive when fragmented? Discuss how your results fit in with the legal narrative and whether they suggest nuanced antitrust remedies that balance oversight and competition.

- **Consider an Overidentification or Multiple Instruments.** Although the instrument relies on three merger episodes, creating separate instruments for each merger (if feasible) and conducting overidentification tests would strengthen claims about exclusion. Alternatively, interacting the baseline shares with year dummies to generate multiple shift-share instruments could allow for falsification.

By addressing these concerns and expanding on the suggested robustness checks, the paper will provide a more airtight identification argument and clearer policy implications.
